H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $535 from $600 and keeps a Buy rating on the shares after the company announced results from the Phase 2 suzetrigene in lumbosacral radiculopathy. The firm believes Vertex’s plan to continue with the Phase 3 trial with innovative approach to deal with the high placebo response is “scientifically justified.”
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals price target lowered to $418 from $509 at Barclays
- Oppenheimer downgrades Vertex after lumbosacral radiculopathy study
- Vertex Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
- Vertex Pharmaceuticals price target lowered to $400 from $451 at RBC Capital
- Vertex Pharmaceuticals price target lowered to $522 from $545 at BofA
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
